大和:維持中鐵塔(0788.HK)目標價1.4港元 評級“沽售”
大和總研發表研究報告指,中鐵塔(0788.HK)第三季的業績稍遜預期,而由於其兩大主要客户共享5G網絡,相信鐵塔在中期內仍受到盈利的考驗。該行重申其“沽售”投資評級,目標價維持1.4港元不變。
大和表示,在第三季業績中未能看見公司中期內的盈利前景,預期中鐵塔在今年產生自由現金流248億元人民幣,而2020-2024年則能每年產生231億元人民幣。該行又料,中鐵塔的自由現金流收益率不及移動運營商強。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.